PCM
ADPT icon

Penserra Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Penserra Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,158
Closed -$56K – 1004
2020
Q3 		$56K Buy
+1,158
New +$48.7K ﹤0.01% 616

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Penserra Capital Management's ADPT Position: Q4 2020 in Review

Penserra Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2020, closing a stake of 1,158 shares — an estimated $56K sold.

Penserra Capital Management first reported a position in ADPT in Q3 2020 and held it in 1 quarter. The position peaked at $56K in Q3 2020. 250 funds tracked by Wall St. Rank hold ADPT as of Q4 2020.

  • Penserra Capital Management reported no remaining Adaptive Biotechnologies position as of Q4 2020 after selling out during the quarter.
  • Penserra Capital Management sold 1,158 Adaptive Biotechnologies shares in Q4 2020, an estimated $56K.
  • Penserra Capital Management first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 1 quarter.
  • Penserra Capital Management's Adaptive Biotechnologies position peaked at $56K in Q3 2020.
  • 250 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.